Ultra-high Resolution Crystal Structure of HIV-1 Protease Mutant Reveals Two Binding Sites for Clinical Inhibitor TMC114

Andrey Y. Kovalevsky, Fengling Liu, Sofiya Leshchenko, Arun K. Ghosh, John M. Louis, Robert W. Harrison, Irene T. Weber

Research output: Contribution to journalArticlepeer-review

133 Scopus citations

Abstract

TMC114 (darunavir) is a promising clinical inhibitor of HIV-1 protease (PR) for treatment of drug resistant HIV/AIDS. We report the ultra-high 0.84 Å resolution crystal structure of the TMC114 complex with PR containing the drug-resistant mutation V32I (PRV32I), and the 1.22 Å resolution structure of a complex with PRM46L. These structures show TMC114 bound at two distinct sites, one in the active-site cavity and the second on the surface of one of the flexible flaps in the PR dimer. Remarkably, TMC114 binds at these two sites simultaneously in two diastereomers related by inversion of the sulfonamide nitrogen. Moreover, the flap site is shaped to accommodate the diastereomer with the S-enantiomeric nitrogen rather than the one with the R-enantiomeric nitrogen. The existence of the second binding site and two diastereomers suggest a mechanism for the high effectiveness of TMC114 on drug-resistant HIV and the potential design of new inhibitors.

Original languageEnglish
Pages (from-to)161-173
Number of pages13
JournalJournal of Molecular Biology
Volume363
Issue number1
DOIs
StatePublished - Oct 13 2006
Externally publishedYes

Funding

FundersFunder number
National Institute of General Medical SciencesU01GM062920

    Keywords

    • HIV-1 protease
    • allosteric binding site
    • darunavir
    • drug resistance
    • ultra-high resolution crystal structure

    Fingerprint

    Dive into the research topics of 'Ultra-high Resolution Crystal Structure of HIV-1 Protease Mutant Reveals Two Binding Sites for Clinical Inhibitor TMC114'. Together they form a unique fingerprint.

    Cite this